For the Inventor, By the Inventor

Enter assignee name

Cincinnati, OH, United States of America

Aerpio Therapeutics, Inc.

USPTO Granted Patents = 35

CIPO Patents = 7

EPO Patents = 22

Forward Citations = 786

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Robert A Shalwitz (19 out of 33 patents)

Kevin Gene Peters (14 out of 34 patents)

Jeffrey Lyle Gray (11 out of 23 patents)

4. Cynthia Monesa Clark (11 out of 16 patents)

5. Ryan Matthew Nichols (11 out of 16 patents)

6. Matthew B Maier (11 out of 16 patents)

7. Kande K D Amarasinghe (11 out of 16 patents)

8. Joseph H Gardner (9 out of 17 patents)

9. John M Janusz (2 out of 36 patents)

10. Alexander Smith (1 out of 16 patents)

11. Boris Gorin (1 out of 31 patents)

12. Jan Oudenes (1 out of 17 patents)

13. Craig Edward Dixon (1 out of 9 patents)

14. Michael Allen Flynn (1 out of 6 patents)

15. James Densmore Copp (1 out of 16 patents)

35 patents: Sort by Forward Citations

1. 10562854 - Prolyl hydroxylase inhibitors (2020-02-18),

2. 10329357 - Treatment of ocular disease (2019-06-25),

3. 10253094 - Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions (2019-04-09),

4. 10220048 - Compositions and methods for treating ocular diseases (2019-03-05),

5. 10150811 - Methods for treating vascular leak syndrome and cancer (2018-12-11),

6. 9994560 - HPTP-β inhibitors (2018-06-12),

7. 9949956 - Compounds, compositions, and methods for preventing metastasis of cancer cells (2018-04-24),

8. 9926367 - Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof (2018-03-27),

9. RE46592 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-30),

10. 9795594 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-24),

11. 9540326 - Prolyl hydroxylase inhibitors (2017-01-10),

12. 9539245 - Combination of immunotherapies with activators of Tie-2 (2017-01-10),

13. 9440963 - Compositions, formulations and methods for treating ocular diseases (2016-09-13),

14. 9388135 - Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones (2016-07-12),

15. 9284285 - Human protein tyrosine phosphatase inhibitors and methods of use (2016-03-15),

Aerpio Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of ocular diseases. Their innovative approach targets the Tie2 pathway to address conditions such as diabetic retinopathy and wet age-related macular degeneration (AMD). Aerpio Therapeutics strives to advance ophthalmic therapies that have the potential to improve patient outcomes and quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

35 Patents

#36 in Cincinnati, OH

#398 in Ohio

#9,420 in US

#18,610 in the World

Cincinnati, OH, United States of America

Aerpio Therapeutics, Inc.

Forward Citations = 786

19 inventors:

Robert A Shalwitz (19 out of 33 patents)

Kevin Gene Peters (14 out of 34 patents)

Jeffrey Lyle Gray (11 out of 23 patents)

4. Cynthia Monesa Clark (11 out of 16 patents)

5. Ryan Matthew Nichols (11 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…